Immuron Limited ( (AU:IMC)) has provided an announcement. Immuron reported unaudited global first-half sales of AUD$4.2 million, up 5% year-on-year, driven primarily by strong performance of its ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Immuron ( (IMRN)) has provided an update.

Immuron Limited (NASDAQ:IMRN) is one of the best performing ASX stocks in 2025. The company released its annual report for 2025 on September 25, in which it reported a 49% growth in global revenue for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Immuron shares this morning surged more than 30% after the company reported robust sales of its traveller’s trots prophylactic, Travelan. We blame the school holidays. In the meantime companies prefer ...

March 2025 Quarter AUD$0.5 million up 28% on prior year March 2025 Year to Date AUD$1.6 million up 86% on prior year MELBOURNE, Australia, April 10, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; ...

Immuron Ltd (NASDAQ:IMRN), a biopharmaceutical company, has announced its highest ever sales for its flagship product, Travelan. The update, disclosed through a recent SEC Form 6-K filing, marks a ...

Immuron Limited reports substantial sales growth for Travelan®, reaching AUD$2.5 million globally in Q4 2024, up 70%. Immuron Limited has reported significant sales growth for its product Travelan®, ...

MELBOURNE, Australia, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce continued ...

December 2024 Quarter AUD$2.5 million up 70% on prior quarter, up 249% on pcp MELBOURNE, Australia, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and ...